Pablo Corral/LinkedIn
Nov 9, 2025, 01:51
Pablo Corral: A True Game Changer in Lipid Management
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”AHA 2025 | CORALreef Lipids Trial
A true game changer in lipid management.
Enliciditide (MK-0616) – the first oral PCSK9 inhibitor – achieved a 57% LDL-C reduction at week 24 and – 50% sustained at week 52 vs placebo (p<0.001).
- Phase 3 trial, 2,912 patients with ASCVD or at high risk, across 14 countries, with excellent safety profile.
- Takeaway: efficacy and safety comparable to injectable PCSK9 inhibitors — but in a once-daily oral tablet.
- A new era in PCSK9 inhibition and cardiovascular prevention.”
Stay updated with Hemostasis Today.
-
May 28, 2026, 09:16Maxime Dely: The Human Connection Behind Stem Cell Donation
-
May 28, 2026, 09:15Heghine Khachatryan: Maternal Health Begins With Recognizing Iron Deficiency Early
-
May 28, 2026, 09:15Alejandro González Veliz: Why Cardiovascular Prevention Matters More Than Intervention
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires